USMJ plans state-of-the-art indoor marijuana cultivation
Dallas, Texas, March 22, 2022 (GLOBE NEWSWIRE) — North American Cannabis Holdings, Inc. (OTC Pink: USMJ) announced today that the company has secured a funding commitment to build an indoor marijuana grow facility at the cutting edge of technology.
The USMJ recently confirmed its eligibility to apply for the newly enacted New York State Adult Use Marijuana Grow License.
In February, New York passed a new law granting temporary marijuana grow licenses to existing hemp businesses.
USMJ has a subsidiary that has been growing hemp for CBD for four years. The subsidiary received an invitation from the New York Office of Cannabis Management (OCM) to apply for the Provisional Adult Cannabis License.
In preparation for the license, USMJ developed plans and secured a funding commitment to build a state-of-the-art indoor cultivation operation.
USMJ is founded on the fundamental belief that cannabis improves people’s lives. Cannabis can fight disease, improve well-being, and do it in an environmentally sustainable way. North American Cannabis Holdings is dedicated to finding the best possible applications for cannabis to serve consumers. The company operates USMJ.com and is dedicated to the continued development of consumer cannabis products that it may incubate in future spin-offs.
USMJ has a spin-off and dividend issue so far in its cannabis incubation operational history having issued shares of Puration, Inc. (OTC Pink: PURA) in the past. USMJ continues to work closely with PURA and recently acquired a CBD sports nutrition drink from PURA under a royalty agreement. The EVERx CBD Sports Nutrition drink acquired by USMJ is bottled by Alkame Holdings, Inc. (OTC Pink: ALKM).
Visit the company’s e-commerce site now and bookmark the site to watch for upcoming announcements and updates: www.USMJ.com
+1 (800) 861-1350
Disclaimer/Safe Harbor: This press release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. Statements reflect the Company’s current beliefs regarding future events that involve risks and uncertainties. These risks include, among others, the expectation that Alkame will achieve significant sales, failure to meet deadlines or performance requirements of the Company’s contracts, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive prices. In light of these uncertainties, the forward-looking events discussed in this press release may not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.